Search

Your search keyword '"Araujo-Mino, Emilio"' showing total 13 results
Start Over Author "Araujo-Mino, Emilio"
13 results on '"Araujo-Mino, Emilio"'

1. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types

Author

Rolfo, Christian, Drilon, Alexander, Hong, David, McCoach, Caroline, Dowlati, Afshin, Lin, Jessica J., Russo, Alessandro, Schram, Alison M., Liu, Stephen V., Nieva, Jorge J., Nguyen, Timmy, Eshaghian, Shahrooz, Morse, Michael, Gettinger, Scott, Mobayed, Mohammad, Goldberg, Sarah, Araujo-Mino, Emilio, Vidula, Neelima, Bardia, Aditya, Subramanian, Janakiraman, Sashital, Deepa, Stinchcombe, Thomas, Kiedrowski, Lesli, Price, Kristin, and Gandara, David R.

Published
2022
Full Text
View/download PDF

2. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types

Author

Rolfo, Christian, primary, Drilon, Alexander, additional, Hong, David, additional, McCoach, Caroline, additional, Dowlati, Afshin, additional, Lin, Jessica J., additional, Russo, Alessandro, additional, Schram, Alison M., additional, Liu, Stephen V., additional, Nieva, Jorge J., additional, Nguyen, Timmy, additional, Eshaghian, Shahrooz, additional, Morse, Michael, additional, Gettinger, Scott, additional, Mobayed, Mohammad, additional, Goldberg, Sarah, additional, Araujo-Mino, Emilio, additional, Vidula, Neelima, additional, Bardia, Aditya, additional, Subramanian, Janakiraman, additional, Sashital, Deepa, additional, Stinchcombe, Thomas, additional, Kiedrowski, Lesli, additional, Price, Kristin, additional, and Gandara, David R., additional

Published
2021
Full Text
View/download PDF

9. Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer

Author

Araujo-Mino, Emilio P., primary, Patt, Yehuda Z., additional, Murray-Krezan, Cristina, additional, Hanson, Joshua A., additional, Bansal, Pranshu, additional, Liem, Ben J., additional, Rajput, Ashwani, additional, Fekrazad, M. Houman, additional, Heywood, Glenory, additional, and Lee, Fa Chyi, additional

Published
2017
Full Text
View/download PDF

11. Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer.

Author

Araujo‐Mino, Emilio P., Patt, Yehuda Z., Murray‐Krezan, Cristina, Hanson, Joshua A., Bansal, Pranshu, Liem, Ben J., Rajput, Ashwani, Fekrazad, M. Houman, Heywood, Glenory, and Lee, Fa Chyi

Subjects
ANAL surgery, RECTUM tumors, THERAPEUTIC use of antimetabolites, ANTIMETABOLITES, CANCER patients, CLINICAL trials, COMBINED modality therapy, CONFIDENCE intervals, DIARRHEA, DRUG tolerance, LIVER, NONSTEROIDAL anti-inflammatory agents, RECTAL diseases, SKIN inflammation, SURVIVAL, CYCLOOXYGENASE 2, OXALIPLATIN, TREATMENT effectiveness, CHEMORADIOTHERAPY, DIAGNOSIS, PROGNOSIS, THERAPEUTICS, TUMOR treatment
Abstract

Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2018
Full Text
View/download PDF

12. Prevalence and Prognostic Significance of CD5 Immunohistochemistry in De-Novo DLBCL in a Western Population Cohort

Author

Bulbul, Ajaz, Thein, Kyaw Zin, Araujo-Mino, Emilio Paul, Yeung, Sai-Ching J, Tsao-Wei, Denice, Huber, Matney, Chouial, Siham, Awasthi, Sanjay, and Khorsand, Masoud

Abstract

Background:Various subsets of Diffuse Large B-cell lymphoma (DLBCL) are distinguished based on molecular and Immunohistochemical features. CD5 expressing DLBCL (CD5+ DLBCL) is increasingly recognized as a subtype of DLBCL with an aggressive disease course in small elderly Asian population cohorts comprising 5-10% of de-novo DLBCL. We attempt to describe its prevalence and prognostic implications in concert with IHC expression profiles of biomarkers

Published
2017
Full Text
View/download PDF

13. Serious Cardiovascular Events and Clinical Outcomes in Secondary Polycythemia: Efficacy of Conventional Phlebotomy and Proposed Hematocrit Target

Author

Bulbul, Ajaz, Araujo-Mino, Emilio Paul, Huber, Matney, Bautista, Adrianna, Thein, Kyaw Zin, Husain, Hatim, Brittany, Flowers, Awasthi, Sanjay, Yeung, Sai-Ching J, and Khorsand, Masoud

Abstract

Background:Recommendations for phlebotomy to treat erythrocytosis of Secondary Polycythemia (SP) are largely reactive and based on limited evidence acknowledging quality of life (QOL) metrics and thrombotic risk over Hct >54%. Unlike the large prospective polycythemia vera study (CYTO-PV), most data with erythrocytosis of SP derive from small retrospective studies and case series. We attempt to evaluate the association of pre-existing cardiovascular (CV) risk factors and Charlson Comorbidity Index (CCI) to determine outcomes with phlebotomy and create therapeutic cut-points to facilitate avoiding serious cardiovascular complications including DVT, pulmonary embolism, myocardial infarction, and cerebrovascular events.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results